Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
GlobalData on MSN4d
GSK CEO addresses declining trust in vaccines following Trump re-electionGSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback